ストックスクリーナーアプリを入手
135.03
0.12%
-0.16
アフターアワーズ：
133.85
-1.18
-0.87%
前日終値:
$135.19
開ける：
$136.66
24時間の取引高:
1.71M
Relative Volume:
1.03
時価総額：
$259.09B
収益：
$54.45B
当期純損益:
$14.42B
株価収益率:
18.41
EPS:
7.333
ネットキャッシュフロー:
$17.15B
1週間 パフォーマンス:
+3.07%
1か月 パフォーマンス:
+2.87%
6か月 パフォーマンス:
+14.34%
1年 パフォーマンス:
+38.11%
1日の値動き範囲:
$134.40
$136.66
1週間の範囲:
$130.46
$136.66
52週間の値動き範囲:
$96.06
$136.66
Novartis Ag Adr Stock (NVS) Company Profile
NVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
135.03 | 259.40B | 54.45B | 14.42B | 17.15B | 7.333 |
|
LLY
Lilly Eli Co
|
1,054.29 | 950.68B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
209.30 | 516.00B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.67 | 401.99B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
98.27 | 248.85B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
| 2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
HSBC Lifts PT on Novartis AG (NVS) to $112 From $106 - Finviz
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - GlobeNewswire Inc.
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report - Insider Monkey
Novartis (NVS) enters $1.7 billion development deal, says report - MSN
Price Over Earnings Overview: Novartis - Sahm
Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease - Benzinga
13 Best ADR Stocks to Invest In - Insider Monkey
Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan - Finviz
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Sahm
Novartis AG (NVS) Announces US FDA Approval of Itvisma - Finviz
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Sahm
Baird Financial Group Inc. Cuts Holdings in Novartis AG $NVS - Defense World
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.
Free cash flow per share of Novartis AG Sponsored ADR – GETTEX:NOTA - TradingView
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz
Why Novartis Stock Topped the Market Today - sharewise.com
Novartis AG Common Stock (NYSE:NVS) Stock Quote - Markets Financial Content
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults - Sahm
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN) - The Globe and Mail
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Finviz
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Sahm
Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring - Sahm
Net margin % of Novartis AG Sponsored ADR – HAM:NOTA - TradingView
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz
Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail
Stocks Generating Improved Relative Strength: Novartis ADR - Investor's Business Daily
Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar
Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India
Novartis completes acquisition of Tourmaline Bio - Novartis
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition - Yahoo Finance
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
1.98%
0.44%
大文字化:
|
ボリューム (24 時間):